PhaseBio Pharmaceuticals Selling, General and Administrative (SG&A) Expenses Growth

Selling, General and Administrative (SG&A) Expenses Growth of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative (SG&A) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending September 29, 2021 was 22.97% (a 272.29% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -313.48%
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2020 was 17.0% (a -86.95% decrease from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was 130.31% (a 19.96% increase from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2018 was 108.63% (a 648.66% increase from previous year)
  • Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending September 29, 2021 was 1.48% (a -167.58% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth decreased by -89.0% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
1.48% -2.19% 2.96% 13.45%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative (SG&A) Expenses Growth of PhaseBio Pharmaceuticals

Most recent Selling, General and Administrative (SG&A) Expenses Growthof PHAS including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 22.97% 6.17% -9.69%
2020 -10.76% 7.78% 34.86% 36.4% 17.0%
2019 63.45% 165.44% 162.16% 260.19% 130.31%
2018 296.64% 108.63%
2017 14.51%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.